Trials / Terminated
TerminatedNCT04088500
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
A Phase 2, Single-arm Open-label Study of Combination Nivolumab and Ipilimumab Retreatment in Advanced Renal Cell Carcinoma Patients Progressing on Nivolumab Maintenance Therapy After Nivolumab and Ipilimumab Induction
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the effectiveness of re-induction with Nivolumab combined with ipilimumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Nivolumab | Specific dose on specific days |
| BIOLOGICAL | Ipilimumab | Specific dose on specific days |
Timeline
- Start date
- 2020-09-03
- Primary completion
- 2021-11-15
- Completion
- 2021-11-15
- First posted
- 2019-09-12
- Last updated
- 2023-01-10
- Results posted
- 2023-01-10
Locations
12 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04088500. Inclusion in this directory is not an endorsement.